Ben Field

Dr Ben Field

Associate Professor of Diabetes and Endocrinology


University roles and responsibilities

  • Caldicott Guardian


    Attanasio R, Žarković M, Papini E, Nagy EV, Negro R, Perros P, Akarsu E, Alevizaki M, Ayvaz G, Bednarczuk T, Beleslin B, Berta E, Bodor M, Borissova AM, Boyanov M, Buffet C, Burlacu MC, Ciric J, Díez JJ, Dobnig H, Fadeyev VV, Field BCT, Fliers E, Führer D (2024) Patients’ persistent symptoms, clinician demographics and geo-economic factors are associated with choice of therapy for hypothyroidism by European thyroid specialists: The “THESIS”* collaboration (*Treatment of Hypothyroidism in Europe by Specialists, an International Survey). Thyroid 2024 epub ahead of print.
    Younes YR, Cron N, Field BCT, Nayyar V, Clark J, Zachariah S, Lakshmipathy K, Isuga JO, Maghsoodi N, Emmanuel J (2024) Proposed treatment strategy for reactive hypoglycaemia. Front Endocrinol 2024; 15: 1332702
    Crabtree TSJ, Adamson K, Bickerton A, Evans A, Phillips S, Gallagher A, Larsen N, Barnes D, Dhatariya K, Field BCT, Idris I, Ryder REJ, ABCD semaglutide audit contributors (2023) The factors predicting glucose and weight response to injectable semaglutide (Ozempic): real-world data from the Association of British Clinical Diabetologists’ audit programme. Br J Diabetes 2023; 23: 94-100
    Žarković M, Attanasio R, Nagy EV, Negro R, Papini E, Perros P, Cohen CA, Akarsu E, Alevizaki M, Ayvaz G, Bednarczuk T, Berta E, Bodor M, Borissova AM, Boyanov M, Buffet C, Burlacu M-C, Ćirić J, Díez JJ, Dobnig H, Fadeyev V, Field BCT, Fliers E, et al (2023) Characteristics of specialists treating hypothyroid patients: the “THESIS” collaborative. Front Endocrinol 2023; 14: 1225202
    Rodway AD, Harris J, Hanna L, Allan C, Casal FP, Giltinan C, Dehghan-Nayeri A, Santos A, Whyte MB, Ntagiantas N, Walton I, Brown R, Skene SS, Pankhania A, Field BCT, Maytham GD, Heiss C (2023) Understanding the impact of COVID-19 on angioplasty service and outcome of patients treated for chronic limb-threatening ischaemia: a single-centre retrospective cohort study. Biomedicines 2023, 11, 2034
    Wilmot EG, Wild SH, Ruan Y, Hadjadj S, Wargny M, Williams MS, Saulnier PJ, Zhu X, Ryder REJ, Pekmezaris R, Marre M, Field BCT, Narendran P, Harris S, Gautier JF, Patel D, Várnai KA, Davies J, Roussel R, Rea R, Gourdy P, Cariou B, Myers A, Khunti K, CORONA (2023) The impact of race/ethnicity on the clinical outcomes of people with type 2 diabetes admitted to hospital with COVID-19: an observational multi-national analysis. Br J Diabetes 2023; 23: 23–30
    Field BCT, Ruan Y, Várnai KA, Davies J, Ryder REJ, Gandhi R, Harris S, Nagi D, Patel D, Kempegowda P, Wild SH, Wilmot EG, Khunti K, Rea R, Narendran P, ABCD COVID-19 Audit Group (2023) A UK nationwide study of adults admitted to hospital with diabetic ketoacidosis or hyperosmolar hyperglycaemic state and COVID-19. Diabetes Obes Metab 2023; 25: 2012–2022
    Rodway AD, Cheal D, Allan C, Pazos-Casal F, Hanna L, Field BCT, Pankhania A, Aston PJ, Skene SS, Maytham GD, Heiss C (2023) Ankle Doppler for cuffless ankle brachial index estimation and peripheral artery disease diagnosis independent of diabetes. J Clin Med 2023; 12: 97
    Joy M, Williams J, Emanuel S, Kar D, Fan X, Delanerolle G, Field BCT, Heiss C, Pollock KG, Sandler B, Arora J, Sheppard JP, Feher M, Hobbs FDR, de Lusignan S (2022) Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014-2019). Heart 2023; 109: 195-201
    Khunti K, Ruan Y, Davies J, Field BCT, Harris S, Kosiborod M, Nagi D, Narendran P, Patel D, Ryder REJ, Várnai KA, Wild SH, Wilmot EG, Rea R; ABCD COVID-19 Diabetes National Audit Investigators (2022) Association between SGLT2 inhibitor treatment and diabetic ketoacidosis and mortality in people with type 2 diabetes admitted to hospital with COVID-19. Diabetes Care 2022; 12: 2838–2843
    de Lusignan S, McGovern A, Hinton W, Whyte M, Munro N, Williams ED, Marcu A, Williams J, Ferreira F, Mount J, Tripathy M, Konstantara E, Field BCT, Feher M (2022) Barriers and facilitators to the initiation of injectable therapies for type 2 diabetes mellitus: a mixed methods study. Diabetes Ther 2022; 13: 1789-809
    Harris S, Ruan Y, Wild SH, Wargny M, Hadjadj S, Delasalle B, Saignes M, Ryder REJ, Field BCT, Narendran P, Zaccardi F, Wilmot EG, Vlacho B, Llauradó G, Mauricio D, Nagi D, Patel D, Várnai KA, Davies J, Gourdy P, Cariou B, Rea R, Khunti K, et al (2022) Association of statin and/or renin-angiotensin-aldosterone system modulating therapy with mortality in adults with diabetes admitted to hospital with COVID-19: A retrospective multicentre European study. Diabetes Metab Syndr Clin Res Rev 2022; 16: 102484
    Crabtree TSJ, Adamson K, Reid H, Barnes D, Sivappriyan S, Bickerton A, Gallen IW, Field BCT, Idris I, Ryder REJ, all ABCD semaglutide audit contributors (2022) Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2022; 24: 1398-401
    Younes YR, Stockley S, Keegan L, O'Donoghue L, Yohannan E, Read L, Williamson JL, Peter J, Lakshmipathy K, Smout V, Nayyar V, Emmanuel J, Zachariah S, Clark J, Field BCT (2022) COVID-19 and dexamethasone-induced hyperglycaemia: Workload implications for diabetes inpatient teams. Diabet Med. 2022; 39(2): e14716
    Williams DM, Davies J, Field BCT, Gandhi R, Harris S, Khunti K, Nagi D, Narendran P, Rea R, Ruan Y, Ryder REJ, Várnai KA, Wild SH, Wilmot EG, Min T, Platts J, Chudleigh R, Stephens JW, Rice S (2021) COVID-19 outcomes in people with diabetes in Wales: a secondary analysis of the ABCD audit. Br J Diabetes 2021; 21: 222-7
    Ruan Y, Ryder REJ, De P, Field BCT, Narendran P, Iqbal A, Gandhi R, Harris S, Nagi D, Aziz U, Karra E, Ghosh S, Hanif W, Edwards AE, Zafar M, Dashora U, Várnai KA, Davies J, Wild SH, Wilmot EG, Webb D, Khunti K, Rea R, ABCD Covid-19 Audit Group (2021) A UK nationwide study of people with type 1 diabetes admitted to hospital with COVID-19 infection. Diabetologia 2021; 64: 1717–24
    Rodway A, Stafford M, Wilding S, Ntagiantas N, Patsiogiannis V, Allan C, Field B, Clark J, Casal FP, Pankhania A, Loosemore T, Heiss C (2021) Day case angioplasty in a secondary care setting - initial experience. Vasa. 2021; 50(3): 202-8.
    Hinton W, Nemeth B, de Lusignan S, Field B, Feher MD, Munro N, Roberts LN, Arya R, Whyte MB (2021) Effect of type 1 diabetes and type 2 diabetes on the risk of venous thromboembolism. Diabet Med 2021; 38: e14452.
    Tan TM, Salem V, Troke RC, Alsafi A, Field BCT, De Silva A, Misra S, Baynes KCR, Donaldson M, Minnion J, Ghatei MA, Godsland IF, Bloom SR (2014) Combination of peptide YY3-36 with GLP-17-36 amide causes an increase in first-phase insulin secretion after IV glucose. J Clin Endocrinol Metab 2014; 99(11): E2317-24
    Tan TM*, Field BCT*, McCullough KA, Troke RC, Chambers ES, Salem V, Gonzalez Maffe J, Baynes KCR, De Silva A, Viardot A, Alsafi A, Frost GS, Ghatei MA, Bloom SR (2013) Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 2013; 62(4): 1131-8 (*joint first author)
    Salem V, Hopkins TG, El-Gayar H, Zac-Varghese S, Goldstone AP, Todd JF, Dhillo W, Field BCT, Martin N, Hatfield E, Donaldson M, Palazzo F, Meeran K, Jackson J, Tan T (2012) Adrenal venous sampling as a diagnostic procedure for primary hyperaldosteronism: experience from a tertiary referral centre. Hormones 2012; 11(2): 151-9
    Tan TM*, Field BCT*, Minnion JS, Cuenco-Shillito J, Chambers ES, Zac-Varghese S, Brindley CJ, Mt-Isa S, Fiorentino F, Ashby D, Ward I, Ghatei MA, Bloom SR (2012) Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. Br J Clin Pharmacol 2012; 73(2): 232-9 (*joint first author)
    Addison ML, Minnion JS, Shillito JC, Suzuki K, Tan TM, Field BCT, Germain-Zito N, Ghatei MA, Bloom SR, Murphy KG (2011) A role for metalloendopeptidases in the breakdown of the gut hormone, PYY3–36. Endocrinology 2011; 152(12): 4630-40
    Sharma S, Radomska-Botelho Moniz A, Triantis I, Michelakis K, Trzebinski J, Azarbadegan A, Field B, Toumazou C, Eames I, Cass A (2011) An integrated silicon sensor with microfluidic chip for monitoring potassium and pH. Microfluid Nanofluid 2011; 10(5): 1119-25
    Liu Y-L, Ford H, Druce MR, Minnion JS, Field BCT, Cuenco-Shillito J, Baxter J, Murphy KG, Ghatei MA, Bloom SR (2010) Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents. Int J Obes 2010; 34(12): 1715-25
    Field BCT*, Wren AM*, Peters V, Baynes KCR, Martin NM, Patterson M, Alsaraf S, Amber V, Wynne K, Ghatei MA, Bloom SR (2010) PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010; 59(7): 1635-9 (*joint first author)
    Druce MR, Minnion JS, Field BCT, Patel SR, Cuenco J, Tilby M, Murphy KG, Ghatei MA, Bloom SR (2009) Investigation of structure-activity relationships of oxyntomodulin using oxyntomodulin analogues. Endocrinology 2009; 150(4): 1712-21
    Feather A, Field BCT, Lumley JSP & Visvanathan R (2007) Medical Finals: Short cases with structured answers, 2nd edition. Pastest, Knutsford, 2007
    Feather A, Domizio P, Field BCT, Knowles, CH, Lumley JSP (2008) EMQs for medical students, Vols 1 & 2, 1st edition. Pastest, Knutsford, 2001, and 2nd edition 2008